Insider Transactions in Q3 2021 at Aurinia Pharmaceuticals Inc. (AUPH)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 21
2021
|
Robert Bindert Huizinga EVP of Research |
SELL
Open market or private sale
|
Direct |
32,500
-12.71%
|
$747,500
$23.86 P/Share
|
|
Sep 21
2021
|
Robert Bindert Huizinga EVP of Research |
BUY
Exercise of conversion of derivative security
|
Direct |
27,136
+9.65%
|
$54,272
$2.92 P/Share
|
|
Sep 21
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
87,500
-33.1%
|
$2,100,000
$24.02 P/Share
|
|
Sep 21
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
87,500
+9.71%
|
$787,500
$9.91 P/Share
|
|
Sep 20
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
28,500
-7.19%
|
$598,500
$21.66 P/Share
|
|
Sep 20
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,500
+12.19%
|
$142,500
$5.3 P/Share
|
|
Sep 14
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
44,000
-10.42%
|
$924,000
$21.76 P/Share
|
|
Sep 14
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
134,000
+15.97%
|
$536,000
$4.6 P/Share
|
|
Sep 14
2021
|
Robert Bindert Huizinga EVP of Research |
SELL
Open market or private sale
|
Direct |
22,500
-17.5%
|
$472,500
$21.75 P/Share
|
|
Sep 14
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
90,000
-33.73%
|
$1,890,000
$21.19 P/Share
|
|
Sep 13
2021
|
Neil Solomons Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+34.3%
|
$450,000
$3.2 P/Share
|
|
Sep 13
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+11.02%
|
$125,000
$5.3 P/Share
|
|
Sep 10
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
150,000
-52.21%
|
$2,850,000
$19.84 P/Share
|
|
Sep 10
2021
|
Robert Bindert Huizinga EVP of Research |
SELL
Open market or private sale
|
Direct |
10,000
-3.68%
|
$190,000
$19.8 P/Share
|
|
Sep 10
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
25,000
-12.38%
|
$475,000
$19.8 P/Share
|
|
Sep 07
2021
|
Robert Bindert Huizinga EVP of Research |
SELL
Open market or private sale
|
Direct |
5,000
-3.48%
|
$90,000
$18.3 P/Share
|
|
Sep 07
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
7,500
-4.07%
|
$135,000
$18.1 P/Share
|
|
Aug 26
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
22,500
-10.88%
|
$382,500
$17.81 P/Share
|
|
Aug 25
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-3.51%
|
$75,000
$15.85 P/Share
|
|
Aug 09
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.36%
|
$80,000
$16.01 P/Share
|
|
Aug 09
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
45,000
-24.03%
|
$720,000
$16.03 P/Share
|
|
Jul 28
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.31%
|
$65,000
$13.86 P/Share
|